Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: Kpti | Rare Historical Photos

Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts

Karyopharm Therapeutics (NASDAQ:KPTI) executives used an H.C. Wainwright BioConnect Conference appearance to highlight upcoming clinical and regulatory milestones for selinexor, the company’s oral nuclear export inhibitor marketed as XPOVIO in multiple myeloma. Chief Executive Officer Richard Pauls

MarketBeat · May 26

Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus

Karyopharm Therapeutics (NASDAQ:KPTI) executives said the company expects to provide a fuller presentation of its Phase 3 SENTRY trial data for selinexor in myelofibrosis at the upcoming ASCO conference, while also outlining expected regulatory engagement and other development priorities during a re

MarketBeat · May 26

Karyopharm Therapeutics Q1 Earnings Call Highlights

Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in endometrial cancer, while reporting higher first-quarter revenue and reaffirming full-year guidance. On th

MarketBeat · May 14

From analysis to the latest developments in health,
read the most diverse news in one place.

Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Wednesday announced comprehensive financing and capital structure transactions expected to provide the company with $100 million of financial flexibility and additional capital, extending the cash runway into the second quarter of 2026.

Benzinga · Oct 8, 2025

Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement

Biogen Inc. (NASDAQ:BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ:KPTI) that it has opted to terminate the companies' Asset Purchase Agreement dated January 24, 2018, as amended. As per the agreement, Karyopharm sold rights of its oral Selective Inhibitor of Nuclear Export compound KPT-350 and certain related assets to Biogen. KPTI received an upfront payment…

Benzinga · Jun 15, 2022

What 5 Analyst Ratings Have To Say About Karyopharm Therapeutics

Over the past 3 months, 5 analysts have published their opinion on Karyopharm Therapeutics (NASDAQ:KPTI) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · Mar 18, 2022

Why Are Karyopharm Shares Trading Lower Today

Karyopharm Therapeutics Inc (NASDAQ: KPTI) stock plunged after an

Benzinga · Mar 2, 2022

Read news from The Economist, FT, and more,
with one subscription

Why Are Karyopharm Shares Plunging Today?

Karyopharm Therapeutics Inc (NASDAQ: KPTI) revealed that executive vice president and chief medical officer Jatin Shah departs for "other professional opportunities."

Benzinga · Feb 22, 2022

Where Karyopharm Therapeutics Stands With Analysts

Karyopharm Therapeutics (NASDAQ:KPTI) has observed the following analyst ratings within the last quarter:

Benzinga · Feb 9, 2022

Karyopharm Shares Fall After Selinexor Data In Endometrial Cancer Patients

Karyopharm Therapeutics Inc's (NASDAQ: KPTI) Phase 3 SIENDO selinexor study has

Benzinga · Feb 8, 2022

Recap: Karyopharm Therapeutics Q4 Earnings

Karyopharm Therapeutics (NASDAQ:KPTI) reported its Q4 earnings results on Tuesday, February 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · Feb 8, 2022

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

424,089 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.